Search Within

Paul Marks

  1. "Lymphoma"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (2)
Groups
  1. Center for Hematologic Malignancies (5)
  2. Department of Medicine (5)
  3. Hematologic Malignancies, Division of (5)
  4. Lymphoma (5)
  5. Nursing (2)
  6. Population Sciences Research Program (2)

More Groups

People
  1. Andrew Zelenetz (4)
  2. Richard Rifkind (4)
  3. Craig Moskowitz (3)
  4. Owen O'connor (3)
  5. William Kelly (3)
  6. Barbara Macgregor-Cortelli (2)

More People

Years
  1. 2006 (1)
  2. 2002 (1)
  3. 2001 (1)
  4. 1998 (1)
  5. 1992 (1)
Publications
  1. Blood (2)
  2. Journal of Biological Chemistry (1)
  3. Journal of Clinical Oncology (1)
  4. Proceedings of the National Academy of Sciences of the United States of America (1)
Publishers
  1. American Society of Hematology (2)
  2. American Society for Biochemistry and Molecular Biology (1)
  3. American Society of Clinical Oncology (1)
  4. National Academy of Sciences (1)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Journal Article

    O'Connor, O. A.; Heaney, M. L.; Schwartz, L.; Richardson, S.; Willim, R.; Macgregor-Cortelli, B.; Curly, T.; Moskowitz, C.; Portlock, C.; Horwitz, S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Meeting Abstract

    O'Connor, O. A.; Richon, V.; Moskowitz, C. H.; Zelenetz, A. D.; Macgregor-Cortelli, B.; Curly, T.; Richardson, S.; Tong, W.; Rifkind, R.; Marks, P.; more...
    Blood (2002)

    Fulltext@MSK | Save
  • Clinical development of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Meeting Abstract

    O'Connor, O. A.; Kelly, W.; Wang, E. S.; Richon, V.; Moskowitz, C.; Tong, W.; Donnelly, G.; Zelenetz, A. D.; Moore, M. A. S.; Rifkind, R. A.; more...
    Blood (2001)

    Fulltext@MSK | Save
  • Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells
    Journal Article

    Siegel, D. S.; Zhang, X.; Feinman, R.; Teitz, T.; Zelenetz, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Michaeli, J.
    Proceedings of the National Academy of Sciences of the United States of America (1998)

    Fulltext@MSK | Save
  • A rise and fall in 1,2-diacylglycerol content signal hexamethylene bisacetamide-induced erythropoiesis
    Journal Article

    Michaeli, J.; Busquets, X.; Orlow, I.; Younes, A.; Colomer, D.; Marks, P. A.; Rifkind, R. A.; Kolesnick, R. N.
    Journal of Biological Chemistry (1992)

    Fulltext@MSK | Save